These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 5155575)

  • 21. Vaccine-induced cytokine responses in a guinea pig model of pulmonary tuberculosis.
    McMurray DN; Allen SS; Jeevan A; Lasco T; Cho H; Skwor T; Yamamoto T; McFarland C; Yoshimura T
    Tuberculosis (Edinb); 2005; 85(5-6):295-301. PubMed ID: 16253558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A.
    Sugawara I; Udagawa T; Taniyama T
    Tuberculosis (Edinb); 2007 Mar; 87(2):94-101. PubMed ID: 16815096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economics of tuberculosis control.
    Waaler HT
    Tubercle; 1968 Mar; 49():Suppl:2-4. PubMed ID: 5659243
    [No Abstract]   [Full Text] [Related]  

  • 24. [Where do we stand with BCG vaccination programme in Japan?].
    Mori T
    Kekkaku; 2001 Apr; 76(4):385-97. PubMed ID: 11398330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberculosis control, without protection from BCG.
    John TJ
    Indian Pediatr; 2000 Jan; 37(1):9-18. PubMed ID: 10745384
    [No Abstract]   [Full Text] [Related]  

  • 26. [Priorities in a modern program of tuberculosis control in countries of Latin America].
    Fraga H
    Bull Int Union Tuberc; 1970 Jun; 43():37-44. PubMed ID: 5425570
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.
    Williams A; Davies A; Marsh PD; Chambers MA; Hewinson RG
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S299-301. PubMed ID: 10875804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCG vaccination of guinea pigs modulates Mycobacterium tuberculosis-induced CCL5 (RANTES) production in vitro and in vivo.
    Skwor TA; Sedberry Allen S; Mackie JT; Russell K; Berghman LR; McMurray DN
    Tuberculosis (Edinb); 2006 Nov; 86(6):419-29. PubMed ID: 16730231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Calmette-Guerin (BCG) vaccination].
    Bonnaud F
    Rev Prat; 1996 Jun; 46(11):1362-7. PubMed ID: 8794620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycobacterium bovis BCG vaccination modulates TNF-alpha production after pulmonary challenge with virulent Mycobacterium tuberculosis in guinea pigs.
    Yamamoto T; Lasco TM; Uchida K; Goto Y; Jeevan A; McFarland C; Ly L; Yamamoto S; McMurray DN
    Tuberculosis (Edinb); 2007 Mar; 87(2):155-65. PubMed ID: 17289434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Protective efficacy of BCG Tokyo 172 in the guinea pig model of pulmonary tuberculosis].
    Yamamoto T; Phalen S; Uchida K; Umemori K; Nojima Y; Horiuchi Y; Goto Y; McMurray DN; Yamamoto S
    Kekkaku; 2000 May; 75(5):379-88. PubMed ID: 10853313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations.
    Basaraba RJ; Izzo AA; Brandt L; Orme IM
    Vaccine; 2006 Jan; 24(3):280-6. PubMed ID: 16153758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Induction of protection in mice by vaccination with a soluble product derived from BCG shaking cultures against experimental tuberculosis].
    Yoneda M
    Kekkaku; 1968 Aug; 43(8):320-4. PubMed ID: 5709293
    [No Abstract]   [Full Text] [Related]  

  • 34. [BCG vaccination in the world].
    Toida I
    Kekkaku; 2000 Jan; 75(1):1-7. PubMed ID: 10689812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis.
    Clark S; Cross ML; Smith A; Court P; Vipond J; Nadian A; Hewinson RG; Batchelor HK; Perrie Y; Williams A; Aldwell FE; Chambers MA
    Vaccine; 2008 Oct; 26(46):5791-7. PubMed ID: 18789366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity.
    Derrick SC; Yang AL; Morris SL
    Vaccine; 2004 Dec; 23(6):780-8. PubMed ID: 15542202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative studies on the immunizing effect of BCG, heat-killed tubercle bacilli (Tb 1), a native tubercle bacterial extract and the tuberculin mother substance (TMS) in experimental guinea pig tuberculosis].
    Siefert G
    Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M; 1966; 62():20-6. PubMed ID: 5952860
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis.
    Aldwell FE; Cross ML; Fitzpatrick CE; Lambeth MR; de Lisle GW; Buddle BM
    Vaccine; 2006 Mar; 24(12):2071-8. PubMed ID: 16332403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The Antitubercular Provincial Associations in the framework of social medicine].
    Monaldi V
    Lotta Tuberc; 1967; 37(1):3-12. PubMed ID: 5252270
    [No Abstract]   [Full Text] [Related]  

  • 40. [Comparative study of BCG vaccines: Polish, Danish and Japanese -- laboratory tests].
    Janaszek W
    Przegl Epidemiol; 1994; 48(3):285-92. PubMed ID: 7938633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.